Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006014816 | Thyroid | PTC | positive regulation of posttranscriptional gene silencing | 21/5968 | 31/18723 | 4.43e-05 | 4.02e-04 | 21 |
GO:003111316 | Thyroid | PTC | regulation of microtubule polymerization | 32/5968 | 55/18723 | 5.03e-05 | 4.47e-04 | 32 |
GO:000836115 | Thyroid | PTC | regulation of cell size | 83/5968 | 181/18723 | 5.45e-05 | 4.84e-04 | 83 |
GO:00328866 | Thyroid | PTC | regulation of microtubule-based process | 105/5968 | 240/18723 | 6.91e-05 | 6.03e-04 | 105 |
GO:00488139 | Thyroid | PTC | dendrite morphogenesis | 69/5968 | 146/18723 | 7.12e-05 | 6.19e-04 | 69 |
GO:00322009 | Thyroid | PTC | telomere organization | 74/5968 | 159/18723 | 7.46e-05 | 6.43e-04 | 74 |
GO:0071897110 | Thyroid | PTC | DNA biosynthetic process | 82/5968 | 180/18723 | 7.98e-05 | 6.81e-04 | 82 |
GO:003221218 | Thyroid | PTC | positive regulation of telomere maintenance via telomerase | 22/5968 | 34/18723 | 8.41e-05 | 7.03e-04 | 22 |
GO:0009266111 | Thyroid | PTC | response to temperature stimulus | 81/5968 | 178/18723 | 9.20e-05 | 7.63e-04 | 81 |
GO:200063716 | Thyroid | PTC | positive regulation of gene silencing by miRNA | 20/5968 | 30/18723 | 9.53e-05 | 7.85e-04 | 20 |
GO:0034612111 | Thyroid | PTC | response to tumor necrosis factor | 109/5968 | 253/18723 | 1.08e-04 | 8.69e-04 | 109 |
GO:00467858 | Thyroid | PTC | microtubule polymerization | 43/5968 | 83/18723 | 1.26e-04 | 9.98e-04 | 43 |
GO:00903986 | Thyroid | PTC | cellular senescence | 47/5968 | 93/18723 | 1.37e-04 | 1.07e-03 | 47 |
GO:00313459 | Thyroid | PTC | negative regulation of cell projection organization | 83/5968 | 186/18723 | 1.72e-04 | 1.32e-03 | 83 |
GO:00519608 | Thyroid | PTC | regulation of nervous system development | 177/5968 | 443/18723 | 1.72e-04 | 1.32e-03 | 177 |
GO:003209118 | Thyroid | PTC | negative regulation of protein binding | 47/5968 | 94/18723 | 1.90e-04 | 1.42e-03 | 47 |
GO:000808819 | Thyroid | PTC | axo-dendritic transport | 39/5968 | 75/18723 | 2.31e-04 | 1.67e-03 | 39 |
GO:00305167 | Thyroid | PTC | regulation of axon extension | 47/5968 | 95/18723 | 2.60e-04 | 1.86e-03 | 47 |
GO:00995187 | Thyroid | PTC | vesicle cytoskeletal trafficking | 38/5968 | 73/18723 | 2.69e-04 | 1.91e-03 | 38 |
GO:2000573111 | Thyroid | PTC | positive regulation of DNA biosynthetic process | 35/5968 | 66/18723 | 2.91e-04 | 2.06e-03 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2 | SNV | Missense_Mutation | | c.5158G>A | p.Gly1720Ser | p.G1720S | P11137 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | novel | c.5438N>G | p.Thr1813Ser | p.T1813S | P11137 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | | c.1633N>C | p.Asp545His | p.D545H | P11137 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.771) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MAP2 | SNV | Missense_Mutation | rs780652765 | c.4724G>A | p.Arg1575Gln | p.R1575Q | P11137 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MAP2 | SNV | Missense_Mutation | | c.2813A>G | p.His938Arg | p.H938R | P11137 | protein_coding | tolerated_low_confidence(0.89) | benign(0.038) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP2 | SNV | Missense_Mutation | | c.2342N>T | p.Gln781Leu | p.Q781L | P11137 | protein_coding | deleterious(0) | benign(0.129) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
MAP2 | SNV | Missense_Mutation | novel | c.2427N>T | p.Met809Ile | p.M809I | P11137 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2 | SNV | Missense_Mutation | novel | c.4259N>T | p.Ser1420Leu | p.S1420L | P11137 | protein_coding | deleterious(0) | benign(0.015) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
MAP2 | SNV | Missense_Mutation | | c.1849N>A | p.Asp617Asn | p.D617N | P11137 | protein_coding | deleterious_low_confidence(0.01) | benign(0.31) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP2 | SNV | Missense_Mutation | novel | c.343N>G | p.Gln115Glu | p.Q115E | P11137 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.977) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |